This CEO Wants To Help Your Nerves Heal Faster. Meet Adam Rogers CEO NervGen – NGEN
Guest
Adam Rogers, MD, Chair, President & Chief Executive Officer at NervGen
Adam’s BIO:
Adam H. Rogers, MD, is the President and Chief Executive Officer of NervGen Pharma and has served as Chairman of the Company’s Board of Directors since July 2025. Dr. Rogers has more than fifteen years of experience advancing novel therapies for diseases with significant unmet medical need.
He is the Principal of Boston-based PFP Biosciences Holdings and previously co-founded Hemera Biosciences in 2010, a clinical-stage biotechnology company developing a one-time investigational gene Therapy administered via outpatient intravitreal injection to preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration.
He served as Hemera’s Chief Executive Officer from 2017 until December 2020, when the rights to its lead program were acquired by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Earlier in his career, Dr. Rogers served as an Assistant Professor of Ophthalmology at the New England Eye Center at Tufts Medical Center and has authored numerous peer-reviewed publications.
Dr. Rogers is a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous and holds an MD from Emory University School of Medicine.
Company Bio
NervGen Pharma (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions.
The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic tetraplegia, as demonstrated in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI.
Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.
